| scholarly article | Q13442814 |
| P2093 | author name string | Subramanian Yegneswaran | |
| John H Griffin | |||
| Laurent O Mosnier | |||
| Andrew J Gale | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| anticoagulant | Q215118 | ||
| drotrecogin alfa | Q412888 | ||
| P304 | page(s) | 1740-1744 | |
| P577 | publication date | 2004-06-03 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Activated protein C variants with normal cytoprotective but reduced anticoagulant activity | |
| P478 | volume | 104 |
| Q34686193 | 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage |
| Q38985138 | 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. |
| Q94464038 | Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation |
| Q64257632 | Activated Protein C in Cutaneous Wound Healing: From Bench to Bedside |
| Q34488999 | Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. |
| Q37085780 | Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1 |
| Q37552150 | Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats |
| Q33798916 | Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact |
| Q37241529 | Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. |
| Q24646845 | Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells |
| Q36997361 | Activated protein C promotes neuroprotection: mechanisms and translation to the clinic |
| Q40056621 | Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis |
| Q39063446 | Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis |
| Q34090836 | Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. |
| Q37403120 | Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells |
| Q88984497 | Activated protein C, protease activated receptor 1, and neuroprotection |
| Q26830499 | Activated protein C: A regulator of human skin epidermal keratinocyte function |
| Q35583397 | Activated protein C: biased for translation. |
| Q37000469 | An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. |
| Q36195195 | An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. |
| Q34050588 | An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C |
| Q36509665 | Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. |
| Q89525768 | C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities |
| Q40326564 | Caspase-3 and -7 mediate apoptosis of human Chang's conjunctival cells induced by enterovirus 70. |
| Q36301525 | Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice |
| Q40127451 | Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation |
| Q47350943 | Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. |
| Q36379329 | Cytoprotective protein C pathways and implications for stroke and neurological disorders |
| Q41773964 | Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. |
| Q27009122 | Cytoprotective-selective activated protein C therapy for ischaemic stroke |
| Q37214257 | Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. |
| Q37142684 | Dissociation of activated protein C functions by elimination of protein S cofactor enhancement |
| Q43186023 | Distinct functions of activated protein C differentially attenuate acute kidney injury. |
| Q37701081 | Down-regulation of the clotting cascade by the protein C pathway |
| Q36607385 | Drotrecogin alfa (activated) in the treatment of severe sepsis |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q36842724 | Effects of anticoagulant strategies on activation of inflammation and coagulation |
| Q34429450 | Effects of exogenous recombinant APC in mouse models of ischemia reperfusion injury and of atherosclerosis |
| Q33954036 | Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier |
| Q36228995 | Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. |
| Q40178873 | Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties |
| Q93204127 | Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen |
| Q37354434 | Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies |
| Q37237490 | Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant |
| Q28277729 | Identification and computationally-based structural interpretation of naturally occurring variants of human protein C |
| Q91923099 | Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons |
| Q40117579 | Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. |
| Q33919300 | Inhaled activated protein C: a new therapy for the prevention of ventilator-induced lung injury? |
| Q36022738 | Interactions between coagulation and complement--their role in inflammation |
| Q37019583 | Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway |
| Q37217154 | Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity |
| Q42929508 | Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice |
| Q44140339 | Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia |
| Q34580126 | Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity |
| Q37065714 | Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. |
| Q48533407 | PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury |
| Q33693490 | Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers |
| Q43667908 | Platelet factor 4 impairs the anticoagulant activity of activated protein C. |
| Q34452632 | Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin |
| Q36319554 | Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke |
| Q81561900 | Preventing kidney cell suicide |
| Q37097085 | Protease-activated receptors in hemostasis |
| Q35591917 | Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke. |
| Q37494702 | Protective mechanisms of activated protein C in severe inflammatory disorders. |
| Q26999113 | Protein C anticoagulant and cytoprotective pathways |
| Q37913122 | Protein C anticoagulant system--anti-inflammatory effects |
| Q34114355 | Protein targets of inflammatory serine proteases and cardiovascular disease |
| Q52722905 | Regulation of immune cell signaling by activated protein C. |
| Q33996371 | Regulation of the protein C anticoagulant and antiinflammatory pathways |
| Q58068803 | Sepsis |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q33870369 | Signal transduction by protease-activated receptors |
| Q37217113 | Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity |
| Q96348307 | Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia |
| Q39338913 | Targeting PAR1: Now What? |
| Q35067408 | The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. |
Search more.